Neglected leishmaniasis

In a report by MSF, of 1,223 new chemical entities marketed between 1975 and 1997, only 13 (1 per cent) were specifically for tropical diseases, and just four could be considered to be products resulting directly from research activities of the pharmaceutical industry (Pecoul et al. 1999). More recently, the DND-WG and the HSPH sent questionnaires to the world s top 20 pharmaceutical companies to assess the level of R D activity in five neglected diseases sleeping sickness, leishmaniasis, Chagas disease, malaria and tuberculosis. Thirteen companies responded, eleven of which completed the questionnaire. In fiscal 2000, eight of the eleven spent nothing on... 

The UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) was established in 1975 in response to appeals from countries where neglected diseases are endemic. TDR addresses ten tropical diseases African trypanosomiasis, dengue, leishmaniasis, schistosomiasis, tuberculosis, Chagas disease, leprosy, lymphatic filariasis, and onchocerciasis. Its mission is ... 

Leishmaniasis is a major group of neglected tropical diseases caused by the protozoan parasite Leishmania. Currently it affects 12 million people in 98 countries, and around 350 million people... 

Collaborative drug discovery projects in the public domain normally focus on neglected tropical diseases (e.g., tuberculosis, malaria, and leishmaniasis) due to the evident medical need, the reduced competition, and associated intellectual property burden. The Medicines for Malaria Venture (MMV) [32] was the first to focus on malaria in a collaborative shion. MMV started in 1999 with initial funding (US 4 million) from the governments of Switzerland and the Netherlands, the UK Department for International Development, the World Bank, and the Rockefeller Foundation. 

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, nonprofit R D organization aiming to deliver new treatments for neglected diseases. In particular, these include sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial parasitic-worm infections, and pediatric HIV. The primary aim is to deliver a total of 11-13 new treatments by 2018. 

D. Bandyopadhyay, S. Samano, J.C. ViUalobos-Rocha, L.E. Sanchez-Torres, B. Nogueda-Torres, G. Rivera, B.K. Banik, A practical green synthesis, and biological evaluation of benzimidazoles against two neglected tropical diseases Chagas and Leishmaniasis. Curr. Med. Chem. 

---